Skip to main navigation Skip to search Skip to main content

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.

Translated title of the contribution: Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionPhase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
Original languageUndefined/Unknown
Pages (from-to)1491-1498
Number of pages8
JournalJournal of Clinical Oncology
Volume24
Issue number10
Publication statusPublished - 2006

Cite this